The project comprises two research lines. In the line 1, human monoclonal antibodiestoward SARS-CoV-2 will be generate and characterized by in vitro functional tests. In theline 2, in vitro tests will be performed to evaluate the efficency of immune responsemediated by antibodies direct to specific tumor molecules.
Not Provided
Inclusion Criteria:
Line 1: - Age >18 at time of signing informed consent form
- Signed informed consent form Line 2: - Primery liver tumor
- Age >18 at time of signing informed consent form
- Signed informed consent form
Exclusion Criteria:
Line 1: - Active or history of neoplastic malignancy
- Active autoimmune disease ongoing treatment with immunosuppressive therapy
- Evidence of positive HIV, HCV, HBV test
- Diabetes
- Failure to sign informed consent form Line 2: - Concomitant diseases with life
expectancy of less than 12 months
- Chronic autoimmune or inflammatory diseases
- Treatment with atezolizumab, bevacizumab, sorafenib, lenvatinib, regorafenib,
cabozantinib, checkpoint inhibitors and tyrosine kinase inhibitors or anti-VEGF
therapies
- Other extrahepatic neoplasms occurring or in the last 3 years except for tumors
resected with curative intent and without evidence of relapse for >3 years prior to
signing informed consent and considered low risk of relapse
- HIV infection
- Failure to sign informed consent form
Fondazione IRCCS Policlinico San Matteo di Pavia
Pavia, Italy
Investigator: Mario Mondelli, MD
Contact: +39 0382 502639
m.mondelli@smatteo.pv.it
Mario Mondelli, MD
+390382502639
m.mondelli@smatteo.pv.it
Barbara Oliviero, Biologist
b.oliviero@smatteo.pv.it
Not Provided